Literature DB >> 22083223

Validation of the Dutch version of the VascuQol questionnaire and the Amsterdam Linear Disability Score in patients with intermittent claudication.

Franceline Alkine Frans1, Suzanne E van Wijngaarden, Rosemarie Met, Mark J W Koelemay.   

Abstract

PURPOSE: To assess the reliability and validity of the Dutch version of the vascular quality of life questionnaire (VascuQol) and the AMC Linear Disability Score (ALDS) in patients with stable intermittent claudication (IC).
METHODS: During a 5-month period we performed a prospective study in which we included every patient with stable IC, who visited our vascular surgery outpatient clinic and consented to participate. Forty consecutive patients filled in the Dutch VascuQol, the ALDS, and Short Form-36 (SF-36). Twenty patients filled in the same questionnaires after 4 weeks. Internal reliability consistencies were expressed as Cronbach's α. Test-retest reliability was expressed as intraclass correlation coefficients (ICC). Construct validity was expressed as Spearman rho correlations between SF-36 and relevant domains of Dutch VascuQol and the ALDS.
RESULTS: Internal reliability consistencies were, respectively, good and excellent for the total scores of VascuQol, SF-36, and ALDS (Cronbach's α. 0.87, 0.89, and 0.92). Test-retest reliability was excellent for the total VascuQol scores [ICC 0.91 (95% CI, 0.78-0.96)], and for the ALDS [ICC 0.90 (95% CI, 0.76-0.96)]. Spearman correlations between VascuQol, ALDS, and SF-36 domains varied from r = 0.34-0.79.
CONCLUSION: The Dutch VascuQol is a valid and reliable questionnaire for assessment of Qol in patients with IC. This study confirms the good clinimetric properties of the ALDS for assessing disability in patients with IC.

Entities:  

Mesh:

Year:  2011        PMID: 22083223     DOI: 10.1007/s11136-011-0060-z

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  4 in total

1.  Item response theory and health outcomes measurement in the 21st century.

Authors:  R D Hays; L S Morales; S P Reise
Journal:  Med Care       Date:  2000-09       Impact factor: 2.983

2.  Cronbach's alpha.

Authors:  J M Bland; D G Altman
Journal:  BMJ       Date:  1997-02-22

3.  The Academic Medical Center Linear Disability Score item bank: psychometric properties of a new generic disability measure in rheumatoid arthritis.

Authors:  Nadine Weisscher; Carla A Wijbrandts; Rob de Haan; Cees A W Glas; Marinus Vermeulen; Paul Peter Tak
Journal:  J Rheumatol       Date:  2007-06       Impact factor: 4.666

4.  The AMC Linear Disability Score in patients with newly diagnosed Parkinson disease.

Authors:  N Weisscher; B Post; R J de Haan; C A W Glas; J D Speelman; M Vermeulen
Journal:  Neurology       Date:  2007-12-04       Impact factor: 9.910

  4 in total
  4 in total

1.  Introducing the Concept of the Minimally Important Difference to Determine a Clinically Relevant Change on Patient-Reported Outcome Measures in Patients with Intermittent Claudication.

Authors:  Anne P Conijn; Wilma Jonkers; Ellen V Rouwet; Anco C Vahl; Jim A Reekers; Mark J W Koelemay
Journal:  Cardiovasc Intervent Radiol       Date:  2015-03-14       Impact factor: 2.740

2.  Quality of life in patients with intermittent claudication.

Authors:  A E Harwood; J P Totty; E Broadbent; G E Smith; I C Chetter
Journal:  Gefasschirurgie       Date:  2017-04-18

3.  Validation of the Vascular quality of life questionnaire - 6 for clinical use in patients with lower limb peripheral arterial disease.

Authors:  Anne Sofie F Larsen; Anne Therese Reiersen; Morten B Jacobsen; Nils-Einar Kløw; Joakim Nordanstig; Mark Morgan; Jarlis Wesche
Journal:  Health Qual Life Outcomes       Date:  2017-09-22       Impact factor: 3.186

4.  Validity and test retest reliability of the vascular quality of life Questionnaire-6: a short form of a disease-specific health-related quality of life instrument for patients with peripheral arterial disease.

Authors:  Christine Kumlien; Joakim Nordanstig; Mats Lundström; Monica Pettersson
Journal:  Health Qual Life Outcomes       Date:  2017-09-29       Impact factor: 3.186

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.